Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Time-Restricted Feeding on Glucose Homeostasis and Quality of Life

11. december 2019 opdateret af: Dr. Ebaa Al Ozairi, Dasman Diabetes Institute

A Pilot Study to Evaluate the Effect of Time-Restricted Feeding on Blood Glucose, Insulin Sensitivity and Quality of Life

Background: Time-restricted feeding can improve insulin sensitivity, and increase fat oxidation in people with prediabetes independent of weight loss. It may also help people to lose weight. However, it has not been tested in people with type 2 diabetes.

Plan of investigation: Participants meeting the eligibility criteria will be randomized to the TRF arm or the continuous eating arm. Both arms with be given a prescribed dietary plan to help them lose 5% of body weight. In the TRF they will permitted to eat between midday and 6pm. In the continuous eating arm they will be allowed to eat between 8am and 11pm. Participants will attend the nutrition clinic every two weeks to be weighed and be given personalized support to help them follow their assigned diet. Prior to starting the diets outcome measures will be taken: Glycaemia will be measured by a glucose tolerance test, and 7-day continuous glucose monitoring. HbA1c will be taken from fasting blood sample. In addition, the fasting sample will be taken for measurement of insulin, lipid profile and inflammatory markers. We will also use questionnaires to assess quality of life, a 3-day food diary to assess compliance to diet especially meal timings. Capillary ketones will also be used to assess whether compliance to the assigned fasting period. Outcome measures will also be taken during 7 days of the second month, and then the final seven days of the last month on the diet. The primary outcome is HbA1c.

Studieoversigt

Detaljeret beskrivelse

Experimental Design

12-week parallel randomised control trial

Recruitment

We will recruit via advertisements outside Dasman using social media and local ads in addition to screening of Dasman Registry for any potential participants. Opportunistic recruitment will also occur by DDI dietitians. Following telephone screening to ensure the potential participant meets initial screening criteria we will carry out a medical screening to ensure the person can take part.

Environment All screening, dietary counselling visits, and placement of the CGM will take place at the Dasman Diabetes Institute (DDI). The institute has extensive space for interventional studies, including screening rooms, body composition assessment and clinical rooms for placement of the CGM monitor.

STUDY INTERVENTIONS

For both groups all participants will be guided towards a 5% weight loss based on individualised energy requirements. The difference will be the hours during which the participants consume their required calories.

  • Time restricted feeding group: Will consume their calories between 12pm and 6pm.
  • Continuous energy restriction group: Will consume their calories between 8am and 11pm.

Participants will be guided towards their weight loss during one-to-one visits at baseline and every 2 weeks for 12 weeks.

Procedures

  • At baseline and follow-up all participants will undergo an oral glucose tolerance test.
  • A blood sample will also be taken for HbA1c, lipid profile, fasting insulin, inflammatory factors and a sample for Biobank. The biobank sample will be stored to enable us, with other researchers at DDI to understand the heterogeneity of type 2 diabetes; whether certain people respond to dietary interventions based on their genetic, epigenetic or metabolomic background; and ultimately will help guide clinical care.
  • Participants will wear Flash Glucose monitoring or other continuous glucose monitoring device to measure their 24-hour blood glucose concentrations during the seven days preceding the start of the dietary intervention, seven days of the second month, and the final seven days of the third month.
  • Participants will also measure their capillary ketones during the first three days of the first month, three days of the second month, and final three days of the third month.
  • Medication changes: prandial medications (insulin or sulphonylurea) will be altered to the timing of meal intake. Any reduction in medication due to changes in glucose will be carried out by the patient's doctor.
  • A quality of life questionnaire: PAID.
  • A 3 day food diary with meal times to check compliance.

Statistical Methods

This is a pilot study. We will recruit 25 people per group. This is based on recommendations for sample sizes for feasibility and pilot studies.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

50

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Must agree to follow time restricted feeding protocol if randomized to the TRF arm.
  • Age 21-65 years
  • T2DM with any diabetes medication
  • BMI of 25-45 kg/m2
  • Wake up at a regular time between 5-8 am
  • Able to provide informed consent.

Exclusion Criteria:

  • Weight loss of more than 5 kg within the past 6 months
  • HbA1c of <6·5% and >12%
  • Serious current or recent illness including cancer or severe or unstable heart failure.
  • Participation in another clinical research trial.
  • Current treatment with anti-obesity drugs.
  • Substance abuse
  • Learning difficulties
  • Presence of an eating disorder
  • Purging behaviour
  • Pregnancy or consideration of pregnancy
  • Hospital admission for depression or use of antipsychotic drugs.
  • Regularly eat within a <9-hour period each day
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: TRF
Eating restricted to between midday and 6pm.
time restricted feeding group
Placebo komparator: Normal timing of food intake.
Eating between 8am and 11pm.
no time restricted feeding

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
HbA1c
Tidsramme: 12 weeks
Change in HbA1c between the intervention and control arms.
12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Body weight
Tidsramme: 12 weeks
Change in body weight between the intervention and control arms.
12 weeks
Insulin sensitivity
Tidsramme: 12 weeks
Change insulin sensitivitiy assessed by OGTT between the intervention and control arms.
12 weeks
Diabetes medications
Tidsramme: 12 weeks
Change in diabetes medications between the intervention and control arms.
12 weeks
Inflammatory markers
Tidsramme: 12 weeks
Change in TNF-alpha in pg/mL between the intervention and control arms.
12 weeks
Inflammatory markers
Tidsramme: 12 weeks
Change in IL-10 in pg/mL between the intervention and control arms.
12 weeks
Inflammatory markers
Tidsramme: 12 weeks
Change in IL-6 in pg/mL between the intervention and control arms.
12 weeks
Inflammatory markers
Tidsramme: 12 weeks
Change in IL-18 in pg/mL between the intervention and control arms.
12 weeks
Inflammatory markers
Tidsramme: 12 weeks
Change in CRP in mg/L between the intervention and control arms.
12 weeks
Inflammatory markers
Tidsramme: 12 weeks
Change in adiponectin in µg/mL the intervention and control arms.
12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. juli 2019

Primær færdiggørelse (Forventet)

1. marts 2020

Studieafslutning (Forventet)

1. marts 2020

Datoer for studieregistrering

Først indsendt

18. august 2019

Først indsendt, der opfyldte QC-kriterier

18. august 2019

Først opslået (Faktiske)

20. august 2019

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

13. december 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. december 2019

Sidst verificeret

1. december 2019

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • RA HM-2019-012

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner